“Buy UCB” | Targets noted on KBC, Ageas, Aperam and WDP | A “shorteur” is reinforced on Ontex (+ Briefing)

November 17, 2020

12:39

After the nice increase recorded on Monday, following the announcement of the effectiveness of Moderna’s Covid-19 vaccine, European markets are the subject of profit taking on Tuesday.

The main European scholarships are in decline this Tuesday noon, under the weight of profit taking after the highest recorded on Monday in reaction to the announcement by Moderna of an efficacy rate of 94.5% for its experimental vaccine against the coronavirus.

Wall Street Should open in scattered order based on US index futures around 12:30 pm.

In Brussels, the Nice 20

fell 0.21% around 12:30 pm, the index of continuously quoted stocks amplifying its loss (-0.55%).

This is Telenet which is at the top of the rare increases in the Bel 20, with a gain of 2%. Ageas, which benefits from the support of a broker, rose 1.4%. UCB, for its part, gained 0.3%. ING has gone to buy the share.

With a decline of 1.6%, AB InBev is red lantern. The brewer is accompanied by WDP, Aedifica and Ship, who drop all three 1%.

Outside Bel 20, the SIR Qrf, climbs 5.5% and Nyrstar by 5.9%. Let us point out again the gains of Jensen (+ 4.6%) and White (+3,7%).

AKKA Technologies (-4,2%), Mithra (-2.5%) and Lotus (-2.1%) are lagging behind. KBC lowered its advice on the speculoos producer.

The Belgian actions briefing

>Aperam

: ING raised its price target to 35 euros, against 26 euros before. The recommendation remains to “buy”.

>UCB

: ING has resumed monitoring the value with a recommendation to “buy” and a target price of 130 euros.

>Colruyt

acquired, last week, 32,000 own shares, at an average unit price of 48.98 euros.

>KBC

: Goldman Sachs raised its price target to 69 euros, against 61 euros before. The recommendation remains to “buy”.

>ING

: Goldman Sachs raised its price target to 10.8 euros, against 10.5 euros before. The recommendation remains to “buy”.

>Umicore

: Credit Suisse has raised its price target to 29 euros, against 28 euros before. The recommendation remains to “underperform”.

>Ageas

: Berenberg raised its target price to 51.9 euros, against 46.9 euros before. The recommendation remains to “buy”.

> S&P Global Ratings has revised upwards, from “A” to “A +”, the “long-term insurer financial strength and issuer credit” ratings ofAgeas SA as well as its main subsidiaries (AG Insurance and Ageas Insurance Limited). The outlook is stable. The debts issued by Ageas, AG Insurance and Ageasfinlux have also been raised by a notch. The press release.

>WDP

: KBC Securities raised its price target to 30 euros, against 29 euros before. The recommendation remains to “keep”.

>GBL

last week acquired 77,539 treasury shares at an average unit price of 78.85 euros.

> BlackRock Investment Management increased its short position on Ontex

rising from 3.42% of the capital to 3.50% on November 11.

>Greenyard

is reaping the benefits of its strategy. Sales up, loss made good, Greenyard is back for its first half with good results and confirms its expectations. Our article.

>VGP

and Allianz announced the completion of two operations via two of their joint ventures involving 19 logistics buildings. The combined value of these transactions reached 424 million euros and they generated gross proceeds of 318 million euros. The press release.

>Care Property Invest

announces the acquisition, subject to conditions precedent, of the care and housing services center located in Murcia. This project is its third acquisition in a short time on the Spanish market. The total investment value for this project amounts to approximately 10.8 million euros. The press release.

>Mithra

submitted, via its commercial partner Libbs, the dossier for Estelle, an oral contraceptive, to the Brazilian regulatory authorities. The press release.

>Lotus Bakeries

: KBC Securities has lowered its recommendation to “hold”, against “accumulate” before. The price target goes from 3,200 euros to 3,600 euros.

>Nyxoah

today announces the successful implantation of the first patient in the pivotal DREAM US study, testing the Genio system to treat obstructive sleep apnea. This study is intended to support an application to bring Genio to market in the United States. The press release.

>Biocartis

announces the publication of a large multicenter comparative study with the Idylla MSI test showing very low failure rates and excellent agreement with reference methods, says the biotech. The press release.

>Biocartis announces the publication of 10 performance studies of its Idylla diagnostic platform at the annual meeting of the Molecular Pathology Association which is being held virtually from November 16 to 20. The press release.

>To keep an eye on this Tuesday. USA. Retail trade in October (2:30 p.m.). Industrial production in October (3.15 p.m.). Home Depot and Walmart results.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.